Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 149Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Large B-Cell, Diffuse 46Leukemia 44Lymphoma, Follicular 39Lymphoma, Non-Hodgkin 35Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia, Myeloid, Acute 25Burkitt Lymphoma 24Neuroblastoma 21Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Lymphoma, Mantle-Cell 14Neoplasms 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 11Sarcoma 10Inflammatory Breast Neoplasms 10Rhabdomyosarcoma 8Recurrence 8Neoplasms, Plasma Cell 8Myelodysplastic Syndromes 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Graft vs Host Disease 8Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Biphenotypic, Acute 7Lung Neoplasms 6

Interventions

pertuzumab 1Trastuzumab 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2 Positive Early Breast Cancer × Cyclophosphamide × Clear all
NCT05883852 2023-06-27

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Fudan University

Phase 3 Recruiting
1,406 enrolled
Breast

HER2 Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡